BRWA
CMPX icon

B. Riley Wealth Advisors’s Compass Therapeutics CMPX Stock Holding History

B. Riley Wealth Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$98.5K – 1428
2024
Q1 		$98.5K Hold
50,000
– – ﹤0.01% 1360
2023
Q4 		$78K Hold
50,000
– – ﹤0.01% 1336
2023
Q3 		$98.5K Buy
50,000
+35,082
+235% +$86.7K ﹤0.01% 1360
2023
Q2 		$47.4K Hold
14,918
– – ﹤0.01% 1484
2023
Q1 		$48.8K Hold
14,918
– – ﹤0.01% 1441
2022
Q4 		$75K Buy
+14,918
New +$59.5K ﹤0.01% 1387

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

B. Riley Wealth Advisors's CMPX Position: Q2 2024 in Review

B. Riley Wealth Advisors sold out of Compass Therapeutics (CMPX) in Q2 2024, closing a stake of 50,000 shares — an estimated $98.5K sold.

B. Riley Wealth Advisors first reported a position in CMPX in Q4 2022 and held it in 6 quarters. The position peaked at $98.5K in Q1 2024. 82 funds tracked by Wall St. Rank hold CMPX as of Q2 2024.

  • B. Riley Wealth Advisors reported no remaining Compass Therapeutics position as of Q2 2024 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 50,000 Compass Therapeutics shares in Q2 2024, an estimated $98.5K.
  • B. Riley Wealth Advisors first reported a position in Compass Therapeutics in Q4 2022 and held it in 6 quarters.
  • B. Riley Wealth Advisors's Compass Therapeutics position peaked at $98.5K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2024.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2024, filed 19 Aug 2024.